2025 has been an important year for mAbsolve. We are pleased to report that two of our commercial licensees have now entered clinical trials using our STR technology.
These are significant milestones for the company. Published clinical data from STR-based products has long been the key missing piece needed to accelerate broader adoption of our technology, and we expect these trials to provide that validation over the coming years.
We continue to license STR widely and look forward to updating you on further progress in 2026.